A field based evaluation of adverse events following MenAfriVac(®)vaccine delivered in a controlled temperature chain (CTC) approach in Benin

INTRODUCTION: An estimated one hundred million African meningitis belt residents have received MenAfriVac(®)meningococcal serogroup A conjugate vaccine. Since October 2012 the vaccine has been licensed for use in a controlled temperature chain (CTC) approach, at temperatures of up to 40°C for up to...

Descripción completa

Detalles Bibliográficos
Autores principales: Steffen, Christoph, Tokplonou, Evariste, Jaillard, Philippe, Dia, Roger, Alladji, Marie N'Deye Bassabi, Gessner, Bradford
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The African Field Epidemiology Network 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282804/
https://www.ncbi.nlm.nih.gov/pubmed/25574320
http://dx.doi.org/10.11604/pamj.2014.18.344.3975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282804/
https://www.ncbi.nlm.nih.gov/pubmed/25574320
http://dx.doi.org/10.11604/pamj.2014.18.344.3975

Ejemplares similares